An Open-Label Prospective Multi-Center Randomized Clinical Trial to Evaluate The Efficacy and Safety Of TheraSphere Followed by Durvalumab (Imfinzi ) With Tremelimumab Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
